PI3K驱动HER2表达:结直肠癌干细胞潜在治疗靶点
该研究旨在明确HER2在结直肠癌干细胞(CR-CSC)中的表达及其作为抗EGFR治疗耐药CRC治疗靶点的潜力。研究利用60例CRC标本的原代球体细胞培养生成CR-CSC小鼠模型进行临床前验证,并通过ChIP-seq和RNA-seq分析机制。结果显示,在CD44v6阳性CR-CSC中,高HER2表达与PI3K/AKT通路激活相关,促进Erbb2基因调控元件乙酰化;靶向HER2联合PI3K和MEK抑制剂可诱导CR-CSC死亡和肿瘤消退,而单靶向PI3K/AKT足以杀死肝转移CR-CSC。
要点
- CD44v6阳性CR-CSC中高HER2表达与PI3K/AKT通路激活相关。
- HER2联合PI3K和MEK抑制可诱导CR-CSC死亡和肿瘤消退。
- 单靶向PI3K/AKT足以杀死肝转移CR-CSC。
核心结论
- 靶向PI3K可杀死肝定植CR-CSC,而同时抑制PI3K、HER2和MEK才能诱导抗EGFR治疗耐药肿瘤消退。
研究设计与样本
- 利用60例CRC标本的原代球体细胞培养生成CR-CSC小鼠模型进行临床前验证,并用ChIP-seq和RNA-seq分析机制。
主要发现
- 在CD44v6阳性CR-CSC中,高HER2表达与PI3K/AKT通路激活相关,促进Erbb2基因调控元件乙酰化。
- HER2靶向联合PI3K和MEK抑制剂诱导CR-CSC死亡和肿瘤异种移植消退,包括携带Kras和Pik3ca突变的肿瘤。
- 癌症相关成纤维细胞释放细胞因子使CR-CSC对PI3K/AKT抑制剂耐药,故需三重靶向。
- 在辅助治疗模型中,单靶向PI3K/AKT足以杀死肝播散CR-CSC。
临床怎么用
- 为辅助和转移 setting 的临床试验设计提供依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Cancer stem cells are responsible for tumour spreading and relapse. Human epidermal growth factor receptor 2 (HER2) expression is a negative prognostic factor in colorectal cancer (CRC) and a potential target in tumours carrying the gene amplification. Our aim was to define the expression of HER2 in colorectal cancer stem cells (CR-CSCs) and its possible role as therapeutic target in CRC resistant to anti- epidermal growth factor receptor (EGFR) therapy. DESIGN: A collection of primary sphere cell cultures obtained from 60 CRC specimens was used to generate CR-CSC mouse avatars to preclinically validate therapeutic options. We also made use of the ChIP-seq analysis for transcriptional evaluation of HER2 activation and global RNA-seq to identify the mechanisms underlying therapy resistance. RESULTS: Here we show that in CD44v6-positive CR-CSCs, high HER2 expression levels are associated with an activation of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, which promotes the acetylation at the regulatory elements of the Erbb2 gene. HER2 targeting in combination with phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase kinase (MEK) inhibitors induces CR-CSC death and regression of tumour xenografts, including those carrying Kras and Pik3ca mutation. Requirement for the triple targeting is due to the presence of cancer-associated fibroblasts, which release cytokines able to confer CR-CSC resistance to PI3K/AKT inhibitors. In contrast, targeting of PI3K/AKT as monotherapy is sufficient to kill liver-disseminating CR-CSCs in a model of adjuvant therapy. CONCLUSIONS: While PI3K targeting kills liver-colonising CR-CSCs, the concomitant inhibition of PI3K, HER2 and MEK is required to induce regression of tumours resistant to anti-EGFR therapies. These data may provide a rationale for designing clinical trials in the adjuvant and metastatic setting.
引用
- Mangiapane LR, Nicotra A, Turdo A, et al. PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells. Gut. 2021. PMID: 33436496. doi:10.1136/gutjnl-2020-323553
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。